Roche reports solid sales growth in the first quarter of 2016
- Details
- Category: Roche
In the first quarter of 2016, Group sales rose 4% to CHF 12.4 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start.
FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expresses
New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment.
AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer's disease, will continue into Phase III of the Phase II/III seamless trial.
Pfizer announces termination of proposed combination with Allergan
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.
Johnson & Johnson announces launch of new global public health strategy at opening of new operations in Africa
- Details
- Category: Johnson & Johnson
Johnson & Johnson today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground global public health operations in Cape Town, South Africa.
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
- Details
- Category: Novo Nordisk
Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016).
More Pharma News ...
- World's first public dengue immunization program starts in the Philippines
- Pandemic influenza vaccine receives positive CHMP opinion
- Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome
- Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban)
- Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
- Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
- AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke